Success Story: Rewiring Cancer Signals Into New Therapeutic Paths: EB1A Approved After RFE for a Chinese Postdoctoral Researcher Advancing Protein and Virus Engineering
Client’s Testimonial:
“Thanks to Wegreened, my EB1A petition was approved! Their expertise, guidance, and attention to detail made the process smooth and stress-free. I highly recommend them to anyone navigating complex immigration cases!”
On February 19th, 2026, we received another EB1A (Alien of Extraordinary Ability) approval for a Postdoctoral Researcher in the field of Bioengineering (Approval Notice).
General Field: Bioengineering
Position at the Time of Case Filing: Postdoctoral Researcher
Country of Origin: China
State of Residence at the Time of Filing: California
Approval Notice Date: February 19th, 2026
Processing Time: 1 year, 11 months, 12 days
Case Summary:
Some biotechnology breakthroughs begin as tools for understanding proteins and end as a new way to design therapies. This EB1A approval highlights a postdoctoral researcher whose work strengthens protein engineering, synthetic biology, and virology methods that can be translated into treatment-relevant strategies. At the time of filing, the client was employed in the United States in a research role aligned with developing protein and synthetic biology systems that support next-generation cancer therapeutics.
Extraordinary Research Contributions
In the petition, we presented the client’s record as centered on original contributions of major significance that expand what researchers can build and measure in complex biological systems. Specifically, this included advances in engineered biological platforms and controllable gene-regulation tools, as well as research that helps connect cancer-associated signaling to precise therapeutic responses. We also described contributions that support antiviral therapeutic development by improving how candidates are designed and evaluated for effectiveness and resistance considerations. Together, these efforts reflect a consistent theme of translating sophisticated bioengineering into practical systems that other researchers can apply.
Academic Contributions and Recognition
To demonstrate sustained influence, the petition documented 5 peer-reviewed journal articles, 1 accepted peer-reviewed journal article, 3 first-authored abstracts, and 1 preprint. This body of work received 415 citations, showing substantial independent reliance by researchers who used the client’s findings as building blocks for their own investigations. The petition also documented at least 14 completed peer reviews, along with additional editorial responsibility, reflecting repeated trust in the client’s judgment to evaluate other experts’ work in a highly selective publication ecosystem.
Expert Endorsements
The petition included independent expert letters describing why the client’s work is influential in bioengineering and why it matters beyond any single project.
One expert stated:
“With her in-depth understanding of protein and gene modification as well as viral biology, [client] has and continues to propose solutions to some of the most serious health concerns facing humanity.”
This endorsement reinforced the petition’s showing that the client’s results are broadly relevant to high-impact biomedical research and are relied upon by other specialists in the field.EB1A Approval and Outlook
The I-140 EB1A petition was filed on March 7th, 2024. After an RFE was issued on December 8th, 2025, the petition was approved on February 19th, 2026. In the filing and RFE response, we demonstrated eligibility through a cohesive record of original contributions of major significance, influential scholarly authorship with strong independent reliance reflected in citations, and sustained peer-review trust, supporting a clear demonstration of extraordinary ability. With this approval, the client is well-positioned to continue advancing bioengineering research that strengthens therapeutic innovation in the United States.